Preclinical News and Research

RSS

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, announced today that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies.

3 Apr 2013

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

3 Apr 2013

V/Q imaging can detect early stages of COPD

In vivo ventilation/perfusion (V/Q) imaging can detect early changes to the lung caused by cigarette smoke exposure and provides a noninvasive method for studying lung dysfunction in preclinical models, according to research published in the April issue of The Journal of Nuclear Medicine.

2 Apr 2013

N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

N30 Pharmaceuticals, Inc., a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, announced today the presentation of key preclinical data for its novel inhibitors of S-nitrosoglutathione reductase.

2 Apr 2013

Inovio Pharmaceuticals reports release of phase II clinical trial results of ChronVac-C

Inovio Pharmaceuticals, Inc. today announced the release of preliminary clinical trial results by its collaborator ChronTech AS of their open label phase II clinical study of ChronVac-C, ChronTech's vaccine to treat hepatitis C virus infection.

2 Apr 2013

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

Ensemble Therapeutics today announced that preclinical data showing the advantages of its Ensemblins, novel macrocyclic compounds against challenging drug targets, will be presented at the 245th American Chemical Society National Meeting being held April 7-11, 2013 in New Orleans, LA.

2 Apr 2013

Cytori receives patent for methods of treating renal diseases using ADRCs

Cytori Therapeutics received US Patent No. 8,404,229 (the '229 patent) for methods of treating renal diseases using adipose-derived regenerative cells (ADRCs).

30 Mar 2013

Data shows efficacy of MANF in neuroprotection 6-hydroxydopamine rat models of Parkinson's disease

Amarantus BioScience, Inc., a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today reported positive preclinical data for its lead therapeutic MANF in neuroprotection 6-hydroxydopamine (6-OHDA) rat models of Parkinson's disease.

28 Mar 2013

KineMed renews research collaboration with Pfizer for advancement of novel diabetes pathways

KineMed Inc. today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.

From Pfizer, Inc. 28 Mar 2013

Neurological researchers study promising new treatment for deadly brain tumors

A promising new treatment for deadly brain tumors taken orally with minimal side effects is being studied by neurological researchers at Rush University Medical Center, Chicago.

28 Mar 2013

IDIBELL signs agreement with Histocell to use patent for acute pulmonary diseases with stem cells

The Bellvitge Biomedical Research Institute has signed a licensing agreement with the Spanish biotech company Histocell to make use of a patent for the treatment of acute pulmonary diseases with mesenchymal stem cells.

28 Mar 2013

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

Oncodesign, a company specializing in drug discovery and providing pharmacological evaluation services in the field of oncology, today announces that it has signed a second research collaboration agreement with Sanofi.

27 Mar 2013

CHOP researchers moving closer to personalized medicine for children with cancer

Pediatric researchers, investigating the biology of brain tumors in children, are finding that crucial differences in how the same gene is mutated may call for different treatments.

27 Mar 2013

Molecular biologist hopes to learn why degenerative disorder affects specific brain cells

Dr. Santosh D'Mello, professor of molecular and cell biology at the University of Texas at Dallas, has received a federal grant for research that may shed light on why and how specific brain cells are affected by Huntington's disease, a devastating, degenerative brain disorder.

27 Mar 2013

arGEN-X advances ARGX-112 into formal preclinical development

arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.

25 Mar 2013

Scientists develop new chemo drug that fights cancer without impacting fertility

A new gentler chemotherapy drug in the form of nanoparticles has been designed by Northwestern Medicine- scientists to be less toxic to a young woman's fertility but extra tough on cancer. This is the first cancer drug tested while in development for its effect on fertility using a novel in vitro test.

25 Mar 2013

Preclinical News and Research

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

V/Q imaging can detect early stages of COPD

N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

Inovio Pharmaceuticals reports release of phase II clinical trial results of ChronVac-C

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

Cytori receives patent for methods of treating renal diseases using ADRCs

Data shows efficacy of MANF in neuroprotection 6-hydroxydopamine rat models of Parkinson's disease

KineMed renews research collaboration with Pfizer for advancement of novel diabetes pathways

Neurological researchers study promising new treatment for deadly brain tumors

IDIBELL signs agreement with Histocell to use patent for acute pulmonary diseases with stem cells

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

CHOP researchers moving closer to personalized medicine for children with cancer

Molecular biologist hopes to learn why degenerative disorder affects specific brain cells

arGEN-X advances ARGX-112 into formal preclinical development

Scientists develop new chemo drug that fights cancer without impacting fertility

Newly discovered molecule could form the basis of anti-malaria drugs

SLU researcher studies effect of bitter melon extract on treating cancer

Last few meals before surgery may affect recovery after surgery, study says

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics